The diagnostics, treatment and five-year survival rates for bladder cancer are largely unchanged since the 1990s. Research into cancer genomics, risk factors and immune therapies could hold the key to progress against this malignant disease.
Layers of risk
Most cases of bladder cancer occur in the cells of the bladder’s innermost lining, the urothelium. In most patients, the cancer has not spread far. These ‘non-muscle-invasive’ tumours are easier to treat and much less lethal than tumours that have grown into the muscle wall or beyond.
Most cases of bladder cancer are the urothelial type. The less-common types are: squamous cell carcinoma, adenocarcinoma, small-cell carcinoma, and sarcoma.
No comfort for old men
Men are about three to four times more likely than women to get bladder cancer, but women are typically diagnosed with more-advanced cancer and have a worse prognosis. Worldwide, bladder cancer is the ninth-most-common cancer and the thirteenth deadliest. But in more-developed countries (below), it poses a bigger threat than many other cancers because fewer new treatment and prevention options have been developed.
Survival and recurrence
Unlike many other cancers, there has been no improvement in survival rates for bladder cancer for three decades.
After surgery, people with bladder cancer should have regular cystoscopies (typically every three months for the first year or two, and then every six months) to see if the cancer returns, as well as imaging and urine tests.
1. GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012; available at http://go.nature.com/2znpnyy
2. Ploussard, G. et al. Eur. Urol. 66, 120–137 (2014).
3. NIH Surveillance, Epidemiology and End Results Program; available at http://go.nature.com/2yk45st
Related links in Nature Research
Related external links
About this article
Current updates on the role of reactive oxygen species in bladder cancer pathogenesis and therapeutics
Clinical and Translational Oncology (2020)
Molecular Carcinogenesis (2020)
Circulating lncRNAs as noninvasive biomarkers in bladder cancer: A diagnostic meta-analysis based on 15 published articles
The International Journal of Biological Markers (2020)
An outcome model for human bladder cancer: A comprehensive study based on weighted gene co‐expression network analysis
Journal of Cellular and Molecular Medicine (2020)
Annals of Human Biology (2020)